Viridian Therapeutics, Inc.\DE (VRDN) Acquisitions (2017)

Viridian Therapeutics, Inc.\DE's (VRDN) quarterly Acquisitions came in at $1.3 million in Q1 2017.

Viridian Therapeutics, Inc.\DE (VRDN) Acquisitions (2017) Analysis & Trends

Viridian Therapeutics, Inc.\DE's Acquisitions history runs 1 years deep, the most recent figure standing at $1.3 million for Q1 2017.

On a quarterly basis, Acquisitions changed N/A year-over-year to $1.3 million in Q1 2017; TTM through Dec 2017 was $1.3 million, a N/A change from a year earlier, with the FY2020 full-year figure at $29.4 million, changed N/A from the prior year.
Acquisitions steadied at $1.3 million in Q1 2017 per VRDN's latest filing.
Across five years, Acquisitions topped out at $1.3 million in Q1 2017 and bottomed at $1.3 million in Q1 2017.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Viridian Therapeutics, Inc.\DE	229.55 Mn	229.55 Mn	-	-

Historic Data

Download Data

Date	Value
Mar 31, 2017	1.28 Mn